The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

Sponsor
First Affiliated Hospital of Zhejiang University
Study ID
NCT03228368
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is designed to evaluate the predicted potential of quantitative T cell repertoire (TCR) of T cell receptor chains using next-generation sequencing (NGS) in the treatment of the anti-programmed death-ligand 1 (PD-L1) antibody atezolizumab in participants with locally advanced or metastatic NSCLC who have progressed during or following a platinum-containing regimen. Treatment may continue until disease progression or unacceptable toxicity.

Key Dates

Start date
Mar 1, 2017
Status verified
Mar 2017
Primary completion
Mar 1, 2018
Completion
Dec 1, 2018

Study Design

Enrollment
10 participants (estimated)

Arms

  • Arm: Atezolizumab (MPDL3280)
    Atezolizumab 1200 milligrams (mg) will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.

Primary Outcome Measure

T cell repertoire [ Time Frame: From Screening until disease progression, death, or loss to follow-up (up to approximately 3 years overall) ]

Central Contacts

  • Director of Department of Thoracic Oncology
    [email protected]
  • The First Affiliated Hospital of College of Medicine, Zhejiang

Related Studies